Ann: onCARlytics with Artemis T cells abstract presented at ASGCT, page-66

It is not a concern for IMU, actually the reason why IMU is progressing onCARlytics.

So far 100s of companies working on CAR-Ts using different targets. But so far only 6 have been approved worldwide by regulators and only 4 of them are currently used. And all targeting CD19. Very successful in bloodcancers but not in solid cancers / tumours.

That now has changed with the CF33 - CD19 combo - called onCARlytics opening the door to tackle solid cancers. The development of CAR-Ts hasn't stopped, new types are in developing aiming at solid cancers. One is CHM's CD17, called CDH17, which soon gets into patients and is expected to be one of the first CAR-Ts to kill solid cancer cells. The pre-clinical results were fascinating and due to PH's reputation - which here often get questioned - he and his Team at CHM / IMU were able to get the licence to develop it further, leaving some of the big pharmas, which were interested as well, empty handed.

It's all about the 90% of cancers that so far have been unable to be cured - the solid ones. And IMU / CHM got a few technologies that already have shown to solve that problem.

That's why we are so convinced that IMU is way undervalued and the market too blind to see what's unfolding. Not to mention some of the posters here who constantly downplay the significance and magnitude for mankind. But in a world where the Putins and Xis have free hands there is no wonder to get posters like that on our forum.

GLTA